62 Participants Needed

Vesleteplirsen for Duchenne Muscular Dystrophy

(MOMENTUM Trial)

Recruiting at 27 trial locations
MI
ST
Overseen BySarepta Therapeutics Inc., For Clinical Trial Information, Select Option 4
Age: < 65
Sex: Male
Trial Phase: Phase 2
Sponsor: Sarepta Therapeutics, Inc.
Must be taking: Corticosteroids
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This trial tests vesleteplirsen, a drug, for safety and tolerance. It involves participants from previous studies and new ones. The goal is to find the highest safe dose and monitor side effects.

Research Team

MD

Medical Director

Principal Investigator

Sarepta Therapeutics, Inc.

Eligibility Criteria

This trial is for individuals with Duchenne Muscular Dystrophy who can potentially benefit from exon 51-skipping treatment. Participants must have previously received SRP-5051 in Part A of this study or in Study 5051-102 to be eligible.

Inclusion Criteria

- Has received prior SRP-5051 treatment in Part A of this study or in Study 5051-102

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Part A: Multiple Ascending Dose

Participants receive escalating dose levels of vesleteplirsen every 4 weeks via IV infusion to determine the maximum tolerated dose

75 weeks
Every 4 weeks (in-person)

Part B: Dose Expansion

Participants receive vesleteplirsen at doses selected from Part A every 4 weeks via IV infusion

Up to 5 years
Every 4 weeks (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • SRP-5051
Trial Overview The study tests Vesleteplirsen (SRP-5051) in two parts: first, finding the highest dose patients can tolerate without severe side effects (Part A), and then checking how well different doses work (Part B).
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Part B: VesleteplirsenExperimental Treatment1 Intervention
Participants received vesleteplirsen at the doses selected based on data from Part A every 4 weeks, via IV infusion, for up to 5 years. This included the participants who rolled over from Part A, as well as the additional participants who enrolled at the beginning of Part B.
Group II: Part A: VesleteplirsenExperimental Treatment1 Intervention
Participants received escalating dose levels of vesleteplirsen, every 4 weeks, via intravenous (IV) infusion for up to 75 weeks during Part A. Once the doses have been selected for Part B, all participants who have completed Part A will transition to Part B.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Sarepta Therapeutics, Inc.

Lead Sponsor

Trials
54
Recruited
34,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security